Main Content


Study title

A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who are not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

  • Principal Investigator: Dr. Stephanie Elkins


The purpose of this study is to compare the effects and safety of the study drug given with Bendamustine to another treatment combination Rituximab in combination with Bendamustine to find out which combination is better for treating large B cell lymphoma.

Who can participate

Those eligible to participate in this study include:

  • Women and men who have large B cell lymphoma and are ages 18 and older.

For more information

  • Teresa Witcher
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson, MS 39216
    (601) 984-6991
  • IRB Number: 2018-0111